Pharmacy

The FDA has approved Pfizer’s talazoparib (Talzenna) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with homologous recombination repair gene mutations. The approval was based on the TALAPRO-3 trial of 599 patients, according…

AstraZeneca is building out a portfolio of targeted cancer drugs, and the first pivotal readout from its wholly owned antibody-drug conjugates is a win: sonesitatug vedotin (Sone-Ve) reduced the risk of death by 42% in previously treated advanced gastric cancer…

Receiving a personalized mRNA-based cancer vaccine alongside immunotherapy lowered the risk of recurrence or death by 42% versus immunotherapy alone in a phase 3 clinical trial of patients with surgically resected stage 2B to 4 melanoma. The vaccine, called intismeran…

Fort Lauderdale, Fla.-based Broward Health has launched bispecific T-cell engager therapy at its flagship Broward Health Medical Center after training care teams across the hospital to support patients receiving the treatment. The first patient, who has a form of lung…

Chemotherapy shortages increased in the third quarter even as the number of active U.S. drug shortages held steady at 225, according to ASHP’s latest quarterly report. Here are seven things to know:

Indianapolis-based Indiana University Health has become the first health system in the U.S. to administer Pixclara, a newly FDA-approved brain cancer imaging drug. The drug is approved for use in adults and children with suspected recurrent glioma, according to an…

The FDA has approved eight oncology indications since Sept. 9. These include label expansions for bladder, colon and breast cancer, and two drugs now approved for previously untreated patients with leukemia and lung cancer. Here are eight recent oncology drug…

The FDA has approved Anktiva as the first treatment specifically for adults with BCG-unresponsive, high-grade papillary-only bladder cancer that has not spread into the bladder muscle. The expanded approval covers Anktiva (nogapendekin alfa inbakicept-pmln) given with Bacillus Calmette-Guérin, according to…

Merck CEO Rob Davis expects the personalized cancer vaccine the company is developing with Moderna to become faster to manufacture over time, according to an Oct. 14 CNBC report. The current turnaround is about six weeks, from sequencing a patient’s…

McKesson and private equity firm CD&R have agreed to buy the nation’s largest independent home infusion provider, a deal that ties one of the biggest drug distributors to a site of care that health systems both refer patients to and…